GSK and Elegen Partner to Bolster R&D with DNA Tech

GSK and Elegen Partner to Develop New Vaccines and Medicines

Pharma giant GSK and venture capital-backed Elegen have announced a collaboration to leverage Elegen’s proprietary technology in DNA manufacturing, aimed at the development of new vaccines and medicines. Under the agreement, Elegen could receive up to $35 million in near-term financial and development support and fees, along with additional revenues related to the sales of its Enfinia DNA product. Furthermore, GSK has the opportunity to make an equity investment in the California-based DNA specialist.